Peregrine Ventures is Israel's first dedicated healthcare and life sciences venture capital fund, founded in 2001 and based in Or Yehuda. The firm invests across all stages—from pre-seed to growth—in medical devices, pharmaceuticals, biotech, and digital health companies.
Average disclosed round size is $36.8M (across 19 rounds with reported amounts).
Portfolio
19
Fund Size
$300M
Top Stage
Unknown
Last 12 Mo
0
Team
BOAZ LIFSCHITZ
Cofounder & Managing General Partner
EYAL LIFSCHITZ
Cofounder & Managing General Partner
TAMIR TAL
Venture Partner
AMIT ALFASI
Investor Relations and Communications
Anna Harel
Financial controller
Elazer R. Edelman
Chairman of the Medical Advisory Board
Inbal Rahamim
Financial controller
Tamar Ben-Zvi
Diagnostics, Business Development
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
| LLutris Pharma | Unknown | $30M | Jan 2025 |
 Bluewhite | Series B | $39M | Jan 2024 |
| BBIOPROTECT LTD | Unknown | $28M | Sep 2023 |
| NNectin Therapeutics | Series A | — | Nov 2022 |
 Cordio | Series A | $18M | Jun 2022 |
| Cordio | Growth | $18M | Jun 2022 |
 Variantyx | Unknown | $41.5M | Jan 2022 |
| RRibon | Series B | $65M | Jul 2021 |
 Aleph Farms | Series B | $105M | Jul 2021 |
 KAHR | Unknown | $46.5M | Jun 2021 |
 Memic | Series D | $96M | Apr 2021 |
| RRaziel Therapeutics | Series C | $22M | Dec 2019 |
 Ribon Therapeutics | Series B | $65M | Jan 2019 |
 CartiHeal | Unknown | $18.3M | Jan 2017 |
| NNLT | Unknown | $8.8M | Jan 2010 |
 Hairstetics | Unknown | — | — |
 Visionsense | Unknown | $20M | — |
 Althea Medical | Unknown | $1.5M | — |
| OOutsense | Series A | $2.2M | — |
 Whitesource | Series C | $35M | — |
| Bluewhite | Series C | $39M | — |
Top Co-Investors
Last updated: 7 October 2026